FDI releases chairside guide for dentists with a focus on caries prevention
mehr
Storys zum Thema Health
Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events
Barcelona, Spain (ots/PRNewswire) - Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not ...
mehrPhilips and HeartFlow Announce Global Collaboration Agreement
Amsterdam and Redwood City, California (ots/PRNewswire) - Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care Royal Philips (http://www.usa.philips.com/) (NYSE: PHG, AEX: PHIA) and HeartFlow, Inc. (http://www.heartflow.com/) announced today that they have entered into a collaboration agreement with the goal of improving access to diagnostic and ...
mehrEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Darmstadt, Germany (ots/PRNewswire) - - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe - MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Marketing authorization includes the 28 countries of the European Union (EU), with first ...
mehrPhilips Showcases Integrated Cardiology Solutions to Deliver Enhanced Patient Care at ESC Congress 2017
Amsterdam and Barcelona, Spain (ots/PRNewswire) - - Spotlights patient-centric cardiovascular solutions for diagnosis, image-guided therapy and connected care through patient monitoring - Demonstrates Philips' commitment to delivering seamless care Royal Philips (http://www.philips.com/digitalpathology) (NYSE: PHG, ...
mehrNICE Recommends Erbitux® in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Decision secures access to Erbitux® for new patients in England with oral cavity tumors - All patients currently receiving Erbitux® will have continued access Merck, a leading science and technology company, announced today that the ...
mehr
LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit
Ballerup, Denmark and Hurley, England (ots/PRNewswire) - New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO Pharma is ranked at number ...
mehrViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
London (ots/PRNewswire) - DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING. This is a ...
mehrResverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
Calgary, Alberta (ots/PRNewswire) - "BETonMACE Phase 3 Trial with apabetalone to expand to include the United States" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the receipt of a positive Type C written response from the Division of Metabolism and Endocrinology Products of the ...
mehrDebiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea
Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
mehrEMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ...
mehrNew Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Sunnyvale, California (ots/PRNewswire) - Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function Accuray Incorporated ...
mehr
LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.[1] ...
mehrCHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Munich (ots/PRNewswire) - - Recommended label update for LIXIANA® provides guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion - Update is based on data from ENSURE-AF, the largest prospective randomised clinical trial of anticoagulation for ...
mehrResverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 ...
mehrALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehrTeva Pharmaceuticals Europe BV
German Federal Joint Committee (G-BA) Confirms Evidence for Additional Benefit for CINQAERO® (reslizumab) in Severe Asthma Patients with an Elevated Eosinophil Count
Amsterdam (ots/PRNewswire) - Positive Assessment in Germany Brings More Patients Closer to Gaining Access to CINQAERO® Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) today announced that the German Federal Joint Committee (G-BA) has confirmed CINQAERO® (reslizumab) provides evidence for a minor additional ...
mehrSequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study for the alfapump® vs. Large Volume Paracentesis for Refractory Ascites in Journal of Hepatology
Zurich (ots) - Sequana Medical AG ("Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology (http://ots.ch/w2er5). The study demonstrated that in patients with ...
mehr
Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress
Bagsvaerd, Denmark (ots/PRNewswire) - Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (http://www.isth.org/) (ISTH) congress from 8-13 July, in Germany. This data will be featured across posters, abstracts and oral ...
mehrDebiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...
mehrALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehrWorld Innovation Summit for Education (WISE)
2017 WISE Awards Finalists Announced
Doha, Qatar (ots/PRNewswire) - Fifteen projects from nine countries have been selected by the World Innovation Summit for Education (WISE) for innovative and impactful approaches to today's most urgent education challenges The World Innovation Summit for Education (WISE) announced the 15 2017 WISE Awards finalist projects. Each year, the WISE Awards recognize and promote innovative projects from around the world that are ...
mehrEthicon Launches New Power Stapler Enabling Extra Control and Precision for Complex Surgeries
Norderstedt, Germany (ots/PRNewswire) - The ECHELON FLEX(TM) GST System now features a 45mm endocutter intended for use in very thick tissue[5], making it suitable across a range of specialties Building on the success of the ECHELON FLEX(TM) 60mm Powered Plus Stapler with Gripping Surface Technology (GST), Ethicon*, a leading global provider of medical devices, today ...
mehrData Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS
Darmstadt, Germany (ots/PRNewswire) - - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T lymphocytes, with lymphocyte counts returning to normal range before the end of Year 2 - The lymphocyte data presented at EAN Congress are consistent with other clinical safety ...
mehr
Philips Unveils IntelliVue X3 in Europe for Continuous Critical Care Patient Monitoring During In-hospital Transport
Amsterdam (ots/PRNewswire) - New technology integrates seamlessly into IntelliVue Patient Monitoring system to deliver real-time data records and enhance clinical decision support Royal Philips (http://www.philips.com/) (NYSE: PHG AEX: PHIA), a global health technology company, today announced the release of the ...
mehrMerck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017
Darmstadt, Germany (ots/PRNewswire) - - New data builds on company's longstanding commitment to MS Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 3rd Congress of the European Academy of Neurology (EAN), taking place from June 24-27, in Amsterdam, ...
mehrCladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical ...
mehrExperts Call for Urgent Action to Address Surgical Site Infections
Geneva (ots/PRNewswire) - Leading specialists at ICPIC congress come together to discuss the issue of SSIs and recent guidelines regarding the use of triclosan-coated sutures in all types of surgery[6] Ethicon* part of the Johnson & Johnson Medical Devices Companies** has joined leading wound closure specialists to discuss recommendations to ease the burden of surgical site infections (SSIs) on patients and costs to ...
mehrShire Pharmaceuticals Group Plc
Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
Zug, Switzerland (ots/PRNewswire) - VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder[1],[2],[3] Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare ...
mehrIUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact(TM) System
Sunnyvale, California (ots/PRNewswire) - The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is providing advanced radiation treatments to cancer patients ...
mehr
Vorherige27282930313233343536Nächste